The BD Veritor™ Plus system provides objective, lab–quality immunoassay test results for healthcare providers and laboratorians in physician offices, clinics, hospitals and IDNs—within minutes. The system streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation. It can also help detect infectious diseases such as Influenza A and B, Respiratory Syncytial Virus (RSV), group A strep, and COVID-19 while the patient is still on site, which may facilitate decision making for earlier intervention.
Order Now
Rapidly identify suspected COVID-19 cases with the BD Veritor™ System SARS-CoV-2 Test. This point-of-care solution provides timely results for effective infection control and patient management.
Differentiate between COVID-19, Influenza A, and Influenza B with a single test using the BD Veritor™ System. This comprehensive solution offers rapid results and efficient workflow.
The first CLIA-waived flu A+B test referenced against PCR, a higher sensitivity standard than culture. Device is ready to insert into reader 10 minutes after same is added.
Quickly detect Respiratory Syncytial Virus (RSV) infections in young patients with the BD Veritor™ RSV Test. This reliable test provides rapid results, aiding in swift treatment and infection control measures.
Accurately diagnose Group A Streptococcus with the BD Veritor™ System Strep A Test. This efficient solution delivers rapid results, enabling prompt treatment initiation.
The new wireless BD Veritor™ Plus System provides lab-quality immunoassay test results within minutes. This fast and accurate solution streamlines the point-of-care (POC) diagnostic workflow and allows providers to quickly review patient results and determine the appropriate treatment in a single consultation.
BD Veritor™ Plus System can help detect infectious diseases, such as Influenza A and B, Respiratory Syncytial Virus (RSV), and Group A Strep while the patient is still on site, which can enable faster decision-making for an earlier intervention opportunity.
The BD Veritor™ Plus Analyzer uses advanced immunoassay technology to detect specific antigens associated with infectious agents. The process involves applying a sample to the test device, which is then read by the analyzer. Results are delivered within minutes, allowing for timely decision-making and patient management.
Help inform appropriate and targeted treatment decisions. Obtain rapid results for multiple respiratory tract infections in 15 minutes or less, enhancing efficiency.
The BD Veritor™ Plus Analyzer improves workflow:
The BD Veritor™ InfoScan module can scan 3 different identifiers (operator ID, specimen ID, and test kit/lot) that can be locally recorded, printed, or downloaded, and reduces hands-on time through automated documentation.
Provides a unique solution to meet each testing site's preference Connectivity: BD Veritor™ InfoSync module provides the same benefits as BD Veritor™ InfoScan. Connects and documents tests results across multiple sites and can integrate with a hospital's electronic medical record or laboratory information system.
Enhances sensitivity by using a proprietary process to produce highly stable, modified colloidal metal particles.
Compensates for background. Nonspecific binding helps improve specificity to reduce false positive results.
The intuitive interface and simple workflow make it easy for healthcare professionals to operate with minimal training.
Its small footprint allows for easy integration into busy clinical environments without taking up valuable space.
A rechargeable battery provides up to 8 hours of continuous testing.
BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world.
Learn More about BD
Click Here